Introduction
Chemoprevention emerges as a realistic option for the control of cancer. Several chemopreventive agents generate oxidative stress, which culminates in cell death (1) (2) (3) (4) . Recently, we proposed that the induction of oxidative stress represents a major proximal event in the mechanism of action of chemopreventive agents (5) . On the other hand, cyclooxygenase (COX)-2, progressively overexpressed during the transition from normalcy to malignancy, has been a major molecular target for the prevention of cancer. Several clinical trials aiming to prevent colon and other cancers using COX-2-specific inhibitors have been conducted. Some of them have shown clear-cut efficacy (6, 7) . This approach has now all but been abandoned due to side effects (8, 9) . Alternative interpretations of the data have been presented, notably the suggestion that COX-2 inhibitors work through non-COX effects (10) . Nevertheless, the generally accepted implication is that COX-2 is central to carcinogenesis and to the action of non-steroidal anti-inflammation drugs (NSAIDs) and COX-2 inhibitors (11, 12) .
Of particular interest have been reports that (i) COX-2 suppresses apoptosis and thus provides a survival advantage to the neoplastic cell (13, 14) and (ii) the expression of COX-2 is induced by oxidative stress in various cells, through mechanisms that may include activation of mitogen-activated protein kinase and/or nuclear factor-jB signaling (15, 16) .
To assess the potential link between the action of chemopreventive agents, oxidative stress and COX-2, we studied two exemplary compounds, sulindac and nitric oxide-donating aspirin (NO-ASA). Sulindac, a conventional NSAID, has a well-documented chemopreventive effect against colon cancer, both in familial adenomatous polyposis and sporadic colon cancer (17) . The novel NO-ASA displays significant anticancer properties, demonstrated in preclinical models of various cancers (18) . NO-ASA consists of a conventional aspirin (ASA) molecule linked covalently via a chemical spacer to -ONO 2 that releases NO (See Supplementary Figure 8 available Carcinogenesis Online). Compared with conventional ASA, NO-ASA is much more potent in inhibiting the growth of many human cancer cell lines and also in preventing colon and pancreatic cancer in animal tumor models (18) .
Here, we report that sulindac sulfide, the active metabolite of sulindac, and NO-ASA induce both oxidative stress and the expression of COX-2, particularly in dying cells. COX-2, however, plays no role in cancer cell growth inhibition by these compounds or in the process of cell death.
Materials and methods

Reagents
Reagents and chemicals were as follows: McCoy's 5a medium (modified), minimum essential medium (Eagle), RPMI 1640, Ham's F12K medium and antibiotics were from Fisher-Mediatech (Herndon, VA); fetal calf serum was from Hyclone (Logan, UT); p-NO-ASA [2-(acetyloxy) benzoic acid 4-(nitrooxymethyl)-phenyl ester], its m-and o-positional isomers as well as the denitrated analogues were synthesized by us (19) ; dihydroethidium (DHE) and 2#,7#-dichlorofluorescein diacetate (DCFDA) were from Calbiochem (San Diego, CA); all other reagents were from Sigma Chemical (St Louis, MO).
Cell culture and cell viability assays BxPC-3, MIA PaCa-2 human pancreatic cancer cell lines, HT29, Caco-2, LoVo HCT-15 human colon adenocarcinoma cell lines and HUVEC, the human endothelial cell line, were from American Type Culture Collection (Manassas, VA). Cells grown as recommended by American Type Culture Collection were seeded at the indicated density and allowed to attach for 24 h, followed by NO-ASA treatment as indicated. Cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (Roche Diagnostics, Indianapolis, IN), following the instructions of the manufacturer.
Western blot
After each treatment, cells were lysed with 1% Triton X-100 lysis buffer and 30 lg of protein cellular lysate was loaded onto sodium dodecyl sulfateelectrophoresis gel and transferred to a polyvinylidene difluoride membrane. COX-1 and COX-2 antibodies were from Cayman Chemical (Ann Harbor, MI). a-Tubulin antibody was from Santa Cruz Biotechnology (Santa Cruz, CA).
Determination of reactive oxygen species
Cells were pretreated with either 5 lM DCFDA or 5 lM DHE in plain RPMI 1640 medium without fetal calf serum or phenol red for 30 min as described (2) . Followed by NO-ASA treatment as indicated, the fluorescent intensity was read by SpectraMax from Molecular Devices (Sunnyvale, CA). For flow cytometry assay, cells were treated with different agents and harvested by trypsinizing and resuspended cells with plain RPMI 1640 medium without fetal calf serum or phenol red containing either 5 lM DCFDA or 5 lM DHE and incubated at 37°C for 30 min. Cells were then read by flow cytometry and data analyzed using the CellQuest software.
Measurement of prostaglandin E 2
A total of 5 Â 10 5 cells/cm 2 seeded overnight were treated with NO-ASA for 6 and 24 h. Prior to adding the NO-ASA, the culture medium was changed to one containing 1% serum. Prostaglandin E 2 (PGE 2 ) levels were determined using the Prostaglandin E 2 EIA Kit from Cayman Chemical and following their instructions.
Abbreviations: ASA, aspirin; BSO, DL-buthionine-(SR)-sulfoximine; COX, cyclooxygenase; DCFDA, 2#,7#-dichlorofluorescein diacetate; DHE, dihydroethidium; IC 50 , median inhibition concentration; mAB, monoclonal antibody; NAC, N-acetyl-cysteine; NADPH, reduced form of nicotinamide adenine dinucleotide phosphate; NO-ASA, nitric oxide-donating aspirin; NSAID, non-steroidal anti-inflammation drug; PGE 2 , prostaglandin E 2 ; ROS, reactive oxygen species; siRNA, short-interfering RNA; X, xanthine; XO, xanthine oxidase. Immunofluorescence microscopy BxPC-3 and HT-29 cells were treated with NO-ASA for 24 h, cytospun onto microscope slides, fixed with 3.7% formaldehyde and immunostained using a monoclonal antibody (mAb) against COX-2 as the primary antibody and fluorescein isothiocyanate-conjugated secondary antibody (Santa Cruz Biotechnology). IgG of the same subtype was used as negative control.
Short-interfering RNA knockdown of cox-2 expression BxPC-3 cells were treated for 72 h with 20 nM COX-2 short-interfering RNA (siRNA) following the protocol recommended by the manufacturer (Dharmacon, Lafayette, CO). After this, cells were seeded in six-well plates and exposed to NO-ASA as indicated. Lipofectamine 2000 (Invitrogen, Carisbad, CA) was the transfection reagent.
Results
NO-ASA induces the expression of COX-2 in human cancer cell lines To investigate whether NO-ASA affects the expression of COX, we studied in various human cancer cell lines the levels of COX-1 and COX-2 in response to NO-ASA or ASA.
HT-29 human colon cancer cells, seeded at 5.0 Â 10 5 cells/cm 2 , were grown overnight and then treated with test compounds for 24 h. The positional isomers of NO-ASA (ortho, meta and para) inhibited cell growth; ASA was much less potent ( Table I ). The median inhibition concentration (IC 50 ) of cell growth for p-NO-ASA was 21.8 ± 4.4 lM (mean ± SEM for this and all subsequent values); these values vary somewhat from those reported previously (20, 21) due to differences in treatment protocol. Consistent with previous findings (22) , the o-isomer was more potent than the p-, and the m-was nearly two orders of magnitude less potent than the other two. All NO-ASA isomers concentration-dependently induced COX-2 expression (Figure 1A) . The m-was the least potent isomer, requiring concentrations 10-to 20-fold higher than the other two to induce COX-2 expression. Figure 1C ). COX-2 was induced by 1 h, increased progressively and reached its maximum by 6 h, remaining stable thereafter at a slightly lower level. The expression of COX-1 remained unchanged. Of interest, the number of cells decreased continuously in response to NO-ASA treatment starting at 1 h, the earliest time of observation.
The induction of COX-2 by NO-ASA was also documented by immunofluorescence ( Figure 1 ). NO-ASA failed to induce the expression of COX-1 at concentrations that induced COX-2 strongly (data not shown). ASA up to 5 mM failed to induce the expression of either COX-1 or COX-2, as determined by immunofluorescence microscopy.
The induced COX-2 is catalytically active
To determine whether the COX-2 induced by NO-ASA was catalytically competent, we measured PGE 2 production in BxPC-3 cells ( Figure 1D ). Cells seeded as previously were washed carefully 24 h later and grown in the presence or absence of NO-ASA or ASA for 6 or 24 h in the medium supplemented with 1% serum (this level of serum does not affect the PG assay). PGE 2 levels in the culture medium were increased concentration-dependently in response to NO-ASA, reaching their maximum at 10 lM NO-ASA (P , 0.01) and decreasing by $69% at 20 lM NO-ASA compared with the 10 lM NO-ASA levels. As expected, the 24 h values were higher than those obtained at 6 h (P , 0.001), but the pattern of response was similar. Treatment of HT-29 cells with NO-ASA (1-100 lM) following the same protocol generated similar results (data not shown). Thus, the COX-2 induced by NO-ASA is catalytically active.
COX-2 induction is pronounced during cell death PGE 2 enhances the growth of colon cancer cells and inhibits their apoptosis (26) , whereas forced COX-2 expression significantly attenuates the induction of apoptosis by NSAIDs (27) . Since the induction of COX-2 by NO-ASA is accompanied by suppressed cell growth, we explored the potential role of COX-2 in cell death. Therefore, we evaluated when in the process of cell death COX-2 expression is induced.
COX-2 expression was determined in cells that were either attached (alive) or floating (dying or already dead). After treating three different cell lines with NO-ASA for 24 h, we observed consistently in all that floating cells expressed much more COX-2 than attached cells (Figure 2A -C).
COX-2 is induced by oxidative stress
Since COX is known to respond to the redox state of the cell (12), we examined the levels of reactive oxygen species (ROS) in HT-29 and BxPC-3 cells treated with NO-ASA or sulindac sulfide. Both compounds increased concentration dependently the levels of ROS, as determined by the general ROS probe DCFDA ( Figures 3A and 4A) .
As shown in Figure 3 , ROS levels were increased significantly (P , 0.001) up to 75-80% in these two cell lines when treated with p-NO-ASA at concentrations up to twice its 24 h IC 50 for cell growth. This effect was accompanied by a concentration-dependent increase of COX-2 expression, which paralleled the ROS levels.
We also examined the levels of ROS in attached and floating BxPC-3 cells. Using as a probe DCFDA, we observed that at NO-ASA 10lM and 15 lM, the ROS levels of floating cells were $4-fold higher (62.09 versus 15.41) than those of attached cells ( Figure 2D ). The corresponding COX-2 expression levels of attached and floating cells were increased, mirroring the increased levels of ROS.
To further evaluate the role of the cell's redox state in COX-2 induction, we treated BxPC-3 cells with the antioxidant agents Tempol (28) and N-acetyl-cysteine (NAC) (29) (Figure 3B ). Pretreatment of BxPC-3 cells with NAC 1 mM for 4 h blocked modestly the induction of COX-2 by NO-ASA (uppermost immunoblot). Pretreatment of the cells with 20 mM NAC dramatically reduced the expression of COX-2, as did Tempol. NAC inhibited the induction of ROS in both HT-29 and BxPC-3 cells (P , 0.001) ( Figure 4A ). We also depleted glutathione (GSH) stores in these cells by pretreatment for 24 h with DLbuthionine-(SR)-sulfoximine (BSO) 100 lM, the specific inhibitor of c-glutamylcysteine synthetase, the rate-limiting enzyme for GSH biosynthesis (30) . At the concentration used here, BSO alone induced the expression COX-2 modestly but greatly potentiated the effect of NO-ASA on COX-2 expression, being clearly synergistic with it ( Figure 3B ). Of note, although the amount of a-tubulin was markedly decreased in cells treated with both p-NO-ASA and BSO (perhaps as a result of cell death), the amount of COX-2 was far greater than that of controls. (Ponceau staining confirmed that the total amount of protein in these lanes was similar to that of the others in this immunoblot.) Finally, the NADPH oxidase inhibitor diphenylene iodonium (31, 32) inhibited the induction of COX-2 by NO-ASA ( Figure 3B ), suggesting an association between O 2 À Á production by this enzyme and COX-2 induction. Figure  4 , after 3 h of treatment with sulindac sulfide at its 24 h IC 50 concentration for growth, ROS levels in BxPC-3 cells were increased by up to 185% (P , 0.01). The increase in ROS levels was followed by enhanced COX-2 (but not COX-1) expression. As with NO-ASA, 4 h pretreatment of the cells with NAC 10 mM abrogated the induction of both ROS and COX-2 ( Figure 4A and B) , an effect paralleled by improved cell survival (data not shown). Longer treatment of BxPC-3 cells with lower concentrations of sulindac sulfide (100 lM for 48 h) also induced COX-2, which was prevented by NAC 10 mM ( Figure 4C ).
Finally, we assessed whether oxidative stress induced by means other than treatment with NO-ASA and sulindac sulfide induces COX-2. We treated BxPC-3 cells with xanthine (X) and xanthine oxidase (XO), a combination which generates O 2 À Á (34) ( Figure  5A-C) . The production of O 2 À Á in response to X/XO was documented at 90 min using the DHE probe for the detection of O 2 À Á. The modest fluorescence response of the DCFDA probe indicates the likely presence of small amounts of other ROS. X/XO concentrationdependently induced the expression of COX-2, evaluated after 12 Chemoprevention, oxidative stress and COX-2 decreased, even though the total amount of protein loaded per lane is the same (Ponceau staining). This probably reflects protein degradation in dying/dead cells. The interesting point here, however, is that the levels of COX-2 are greatly increased, in agreement with all our previous findings.
COX-2 is not required for cell growth inhibition and does not cause cell death COX-2 is the molecular target of the chemopreventive COX-2 inhibitors (11) . The implication is that inactivation of COX-2 causes the death of the neoplastic cell. On the other hand, our data show that NO-ASA and sulindac increase the cellular levels of ROS and COX-2 and these events are critical to the cell death induced by these two agents. The implication here is that COX-2 may participate in the induction of cell death by NSAIDs.
To resolve these issues, we knocked down the expression of cox-2 in BxPC-3 cells using a cox-2-specific siRNA oligonucleotide. In contrast to those transfected with non-specific siRNA or untransfected cells, cells transfected with specific cox-2 siRNA showed essentially no COX-2 expression ( Figure 6A ). When these cells were treated with 5 or 10 lM NO-ASA for another 24 h, the effect of NO-ASA on cell growth (number of cells alive) was about the same, regardless of the level of COX-2 expression. Thus, inhibition of COX-2 is not required for the induction of cell death by NO-ASA.
To assess whether COX-2 participates in the induction of cell death, BxPC-3 cells were treated with or without the pan-caspase inhibitor zVAD 25 lM, followed by p-NO-ASA for 18 h ( Figure 6B ). NO-ASA induced apoptosis concentration-dependently. Apoptotic cells [annexin (þ) and propidium iodide (À)] increased from 2.9% in control to 18.8% in cells treated with NO-ASA 20 mM (P , 0.01), whereas those representing secondary necrosis [annexin (þ) and propidium iodide (þ)] increased from 2.6 to 27.3% (P , 0.01), respectively. Pretreatment with zVAD prevented these changes to a large extent, with the corresponding values being reduced to 6.5 and 17.8% (P , 0.01) (NO-ASA 10 lM gave intermediate responses). ROS levels remained unchanged in response to zVAD evidenced by DCFDA staining ( Figure 6B ). Despite the reduction in cell death by zVAD, the induction of COX-2 did not change. These findings indicate that cell death is independent of COX-2 induction and appears responsive only to ROS. Structure-activity relationship for the induction of COX-2 by NO-ASA As shown above, the three positional isomers of NO-ASA induce COX-2 with different potency. The -ONO 2 moiety of NO-ASA releases NO, a property that defines NO-NSAIDs. Denitrated p-NO-ASA (-OH in the place of -ONO 2 ) failed to induce oxidative stress and had no effect on COX-2 expression; denitrated m-and o-isomers gave similar results (supplementary Figure 2 is available at Carcinogenesis Online and data not shown). These data indicate that the -ONO 2 moiety is required for these effects. This result is consistent with the notion that the spacer of NO-ASA may be responsible for its effects (35) .
Discussion
Our findings document that in cancer cell lines two chemopreventive agents induce oxidative stress, which leads to overexpression of COX-2. The induction of COX-2 by ROS is independent of the agent causing oxidative stress and also of the tissue origin of the cell lines and their phenotype (malignant or not) and is enhanced in dying cells, whose ROS levels are increased further. COX-2 does not participate in the process of cell death or in the cell growth inhibitory effect of these agents.
The induction of COX-2 by NO-ASA was documented both by immunoblotting and by fluorescent microscopy. The induced COX-2 was not an aberrant, metabolically inactive form of COX-2 crossreacting with the antibody used for its detection; rather, it was catalytically competent as evidenced by its ability to produce PGE 2 .
The effect of NO-ASA and sulindac sulfide on COX-2 expression is specific since conventional ASA failed to have such an effect and the expression of COX-1 remained unchanged. Of note, cox-null colon and pancreatic cell lines (24) failed to express COX-2 when treated with NO-ASA. The induction of COX-2 occurred in response to all three isomers of NO-ASA, and the levels of COX-2 reflected the cancer cell growth inhibitory potency of each isomer [m-NO-ASA is the least potent (20) ]. The induction of COX-2 was both time and concentration dependent and represented a generalized effect in terms of (i) the tissue origin of the cell lines in which it occurs; (ii) their phenotype and (iii) the chemical structure of the compound that induces it. NO-ASA induced COX-2 in four different cell lines; the three of them that are derived from human cancers display a malignant phenotype, whereas the fourth (HU-VE-EC) is a normal cell line. Moreover, two structurally different compounds, NO-ASA and sulindac sulfide, induced COX-2.
The oxidative stress generated by these two chemopreventive agents was responsible for the induction of COX-2. Two antioxidants abrogated this phenomenon, whereas depletion of cellular GSH, the main antioxidant in mammalian cells, induced COX-2 expression, which was enhanced further by NO-ASA. The role of ROS in the induction of COX-2 is also underscored by the induction of COX-2 by O 2 À Á, which was generated by treating cells with X/XO, or by H 2 O 2 directly. Consistent with this notion, diphenylene iodonium, the inhibitor of NADPH oxidase, the enzyme generating O 2 À Á, suppressed COX-2.
Compared with attached cells, floating cells (they are either dying or already dead) had more ROS and more COX-2. The increased levels of COX-2, however, did not contribute to cell death by these agents. First, NO-ASA inhibited the growth of cells whose COX-2 expression was knocked down by siRNA; second, when cell death was blocked by a pan-caspase inhibitor, the induced COX-2 did not change. It is unclear, however, why the dying cell has increased COX-2 levels. One possibility is that COX-2 levels may be increased as a result of slower protein degradation during cell death. Alternatively, the cell, dying in response to an exogenous agent, may try to abort its death by overexpressing a protein like COX-2, which is known to reduce apoptotic susceptibility (27) .
Our results support three potentially useful ideas: (i) the concept that ROS is a critical component of the action of chemopreventive agents (5); (ii) the notion that COX-2 may not be an ideal target for chemoprevention (10) and (iii) the possibility that COX-2 may be overexpressed in cancer cells due to their state of oxidative stress (12, 36, 37) . It is conceivable that, if further substantiated, these ideas may inform the rational design of chemotherapeutic strategies, in particular the choice of agents in combination approaches.
In summary, our data establish that two chemopreventive agents, NO-ASA and sulindac sulfide, generate a state of oxidative stress in various cell lines, leading to overexpression of COX-2. The induction of COX-2, however, does not contribute to the cell death induced by these agents. Our data suggest that further studies are needed to assess the role of ROS as part of a general mechanism of action of chemopreventive agents against cancer. Supplementary Figures 1 and 2 can be found at http://carcin. oxfordjournals.org/ Funding National Institutes of Health (2R01 CA92423 and R01 CA101019).
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